

Keyword index

A-216546

Antagonist; Endothelin ET_A receptor (Wu-Wong, J.R. (366) 189)

Acetylcholine

Scopolamine; Turning behavior; Methylxanthine; Adenosine–dopamine receptor interaction (Casas, M. (366) 1)

Adenosine–dopamine receptor interaction

Acetylcholine; Scopolamine; Turning behavior; Methylxanthine (Casas, M. (366) 1)

Adrenal medulla chromaffin cell

Ca²⁺ concentration, cytosolic free; Phorbol ester; Protein kinase C; Ca²⁺ channel, voltage-sensitive (Sena, C.M. (366) 281)

α₂-Adrenoceptor

Tail artery rat; mRNA (McNeill, A.M.C. (366) 233)

α₂-Adrenoceptor antagonist

Atipamezole; Neuropathic pain; Allodynia; Animal model (Xu, M. (366) 41)

α₂-Adrenoceptor subtype

Locus coeruleus; Noradrenaline; Voltammetry, in vivo (Callado, L.F. (366) 35)

α₁-Adrenoceptor subtype, α_{1A}, α_{1L}

Prostate; Oxymetazoline; (Rat) (Hiraoka, Y. (366) 119)

Aequorin

NMDA receptor; Promoter inducible; Reporter gene assay (Renard, S. (366) 319)

Aging

Gastrin; Nitric oxide (NO) synthase; Gastric mucin biosynthesis (Ichikawa, T. (366) 87)

Allodynia

α₂-Adrenoceptor antagonist; Atipamezole; Neuropathic pain; Animal model (Xu, M. (366) 41)

Alzheimer disease

Tetrahydroaminoacridine; D-Cycloserine; Water maze; Passive avoidance (Riekkinen Jr., P. (366) 13)

(R)-α-methylhistamine

Histamine H₃ receptor; Saphenous human vein; Sympathetic neuron; Electrical field stimulation; Cryopreservation (Valentine, A.F. (366) 73)

Amidotrizoate

Cochlea; Hydrocortisone; ATP; Microcirculation disorder; Reactive oxygen species (Nagura, M. (366) 47)

cAMP

VIP (vasoactive intestinal polypeptide); S-nitrosylated-VIP; Nitric oxide (NO); S-nitrosoglutathione (GSNO); NANC (non-adrenergic non-cholinergic); Smooth muscle; cGMP (Jia, L. (366) 79)

Animal model

α₂-Adrenoceptor antagonist; Atipamezole; Neuropathic pain; Allodynia (Xu, M. (366) 41)

Antagonist

A-216546; Endothelin ET_A receptor (Wu-Wong, J.R. (366) 189)

Antiepileptic drug

Nitric oxide (NO); L-Arginine; N^G-Nitro-L-arginine; Pentylentetrazol; Seizure (Czuczwar, S.J. (366) 137)

Aorta, rat

K⁺ (K_{ATP}) channel, ATP-sensitive; Endothelium (Tanaka, Y. (366) R9)

Ap₅A (diadenosine pentaphosphate)

ATP; Diadenosine polyphosphate; Ip₅I (diinosine pentaphosphate); Ca²⁺ channels, voltage-dependent (Pintor, J. (366) 159)

L-Arginine

Nitric oxide (NO); N^G-Nitro-L-arginine; Antiepileptic drug; Pentylentetrazol; Seizure (Czuczwar, S.J. (366) 137)

Arterial contraction

‘Superficial buffer barrier’ hypothesis; Sarcoplasmic reticulum; Ca²⁺-ATPase; Ca²⁺ level, cellular; Ca²⁺ influx; Ca²⁺ channel, L-type (Asano, M. (366) 61)

Atipamezole

α₂-Adrenoceptor antagonist; Neuropathic pain; Allodynia; Animal model (Xu, M. (366) 41)

ATP

Cochlea; Hydrocortisone; Amidotrizoate; Microcirculation disorder; Reactive oxygen species (Nagura, M. (366) 47)

Ap₅A (diadenosine pentaphosphate); Diadenosine polyphosphate; Ip₅I (diinosine pentaphosphate); Ca²⁺ channels, voltage-dependent (Pintor, J. (366) 159)

Thapsigargin; Carbachol; Endothelium; EDRF (endothelium-derived relaxing factor); Ca²⁺ level; Cytosolic (Amano, K.-i. (366) 215)

β-adrenoceptor antagonist

Trabecula; Propranolol; Myocardium; Oxygen-free radical; (Rabbit) (Janssen, P.M.L. (366) 223)

BHQ (2,5-di-*t*-butyl-1,4-benzohydroquinone)

Nitric oxide (NO); Superoxide anion; Ca²⁺ channel, Ni²⁺-sensitive (Fusi, F. (366) 181)

Brain oedema

Cholinergic mediation; Monoamine oxidase-B inhibition; Motor function; Neuroprotection; Spatial memory (Huang, W. (366) 127)

Bromocriptine

Pergolide; Pramipexole; Ropinirole; Parkinson's disease; Recombinant receptor (Perachon, S. (366) 293)

Bronchoconstriction

DP-1904; OKY-046; Thromboxane synthetase inhibitor; (Guinea pig); (Rat) (Takami, M. (366) 253)

Ca²⁺-ATPase

'Superficial buffer barrier' hypothesis; Sarcoplasmic reticulum; Ca²⁺ level, cellular; Ca²⁺ influx; Ca²⁺ channel, L-type; Arterial contraction (Asano, M. (366) 61)

Ca²⁺ channel, L-type

'Superficial buffer barrier' hypothesis; Sarcoplasmic reticulum; Ca²⁺-ATPase; Ca²⁺ level, cellular; Ca²⁺ influx; Arterial contraction (Asano, M. (366) 61)

Ca²⁺ channel, Ni²⁺-sensitive

BHQ (2,5-di-*t*-butyl-1,4-benzohydroquinone); Nitric oxide (NO); Super-oxide anion (Fusi, F. (366) 181)

Ca²⁺ channels, voltage-dependent

ATP; Ap₅A (diadenosine pentaphosphate); Diadenosine polyphosphate; Ip₅I (diinosine pentaphosphate) (Pintor, J. (366) 159)

Ca²⁺ channel, voltage-sensitive

Adrenal medulla chromaffin cell; Ca²⁺ concentration, cytosolic free; Phorbol ester; Protein kinase C (Sena, C.M. (366) 281)

Ca²⁺ concentration

NMDA receptor; 2,2,2-Trichloroethanol; Intracellular (Scheibler, P. (366) R1)

Ca²⁺ concentration, cytosolic free

Adrenal medulla chromaffin cell; Phorbol ester; Protein kinase C; Ca²⁺ channel, voltage-sensitive (Sena, C.M. (366) 281)

Ca²⁺, cytosolic

Dotarizine; Flunarizine; Chromaffin cell viability (Novalbos, J. (366) 309)

Ca²⁺ influx

'Superficial buffer barrier' hypothesis; Sarcoplasmic reticulum; Ca²⁺-ATPase; Ca²⁺ level, cellular; Ca²⁺ channel, L-type; Arterial contraction (Asano, M. (366) 61)

Ca²⁺ level

ATP; Thapsigargin; Carbachol; Endothelium; EDRF (endothelium-derived relaxing factor); Cytosolic (Amano, K.-i. (366) 215)

Ca²⁺ level, cellular

'Superficial buffer barrier' hypothesis; Sarcoplasmic reticulum; Ca²⁺-ATPase; Ca²⁺ influx; Ca²⁺ channel, L-type; Arterial contraction (Asano, M. (366) 61)

Carbachol

ATP; Thapsigargin; Endothelium; EDRF (endothelium-derived relaxing factor); Ca²⁺ level; Cytosolic (Amano, K.-i. (366) 215)

Carrier-mediated release

Spinal cord; Ischemia; Noradrenaline release; NMDA receptor; Non-NMDA receptor; Dizocilpine; LY300168 (GYKI-53655); LY303070 (GYKI-53784) (Nakai, T. (366) 143)

Chiral inversion

N^G-Nitro-L-arginine; N^G-Nitro-D-arginine; Nitric oxide (NO); (Ex vivo); (In vivo) (Wang, Y.-X. (366) 175)

Cholinergic mediation

Brain oedema; Monoamine oxidase-B inhibition; Motor function; Neuro-protection; Spatial memory (Huang, W. (366) 127)

Chromaffin cell viability

Dotarizine; Flunarizine; Ca²⁺, cytosolic (Novalbos, J. (366) 309)

Clomipramine

Myosin heavy chain; Masticatory behaviour; (Rat) (Hartmann, N. (366) 19)

Clozapine

Dopamine; Electrophysiology (Melis, M. (366) R11)

Cochlea

Hydrocortisone; Amidotrizoate; ATP; Microcirculation disorder; Reactive oxygen species (Nagura, M. (366) 47)

Coronary artery thrombosis

GPIIb/IIIa receptor antagonist; Platelet aggregation; Myocardial infarction; SM-20302 (Huang, J. (366) 203)

Cryopreservation

Histamine H₃ receptor; (*R*)- α -methylhistamine; Saphenous human vein; Sympathetic neuron; Electrical field stimulation (Valentine, A.F. (366) 73)

D-Cycloserine

Tetrahydroaminoacridine; Water maze; Passive avoidance; Alzheimer disease (Riekkinen Jr., P. (366) 13)

Cystic fibrosis

G protein; Lung membrane; Nucleotide; Signal transduction (Laubinger, W. (366) 93)

Cytochrome P-4502D6

Extensive metabolizer; [³H]GBR 12935 binding; Platelet, human; Piperazine acceptor site; Poor metabolizer (Norlén, M. (366) 329)

Cytosolic

ATP; Thapsigargin; Carbachol; Endothelium; EDRF (endothelium-derived relaxing factor); Ca²⁺ level (Amano, K.-i. (366) 215)

DADLE ([D-Ala², D-Leu⁵]enkephalin)

c-fos mRNA; Methamphetamine; Opioid (Hayashi, T. (366) R7)

DCG = IV ((2S,1R,2R,3R)-2-(2S,1'R,2'R,3'R)-2 (2'3'-dicarboxycyclopropyl)glycine)

mGluR receptor, group II; MCPG ((+)- α -methyl-4-carboxyphenylglycine); EGLU ((S)- α -ethylglutamate); NAAG (*N*-acetylasparylglutamate); Hippocampus; Long-term depression (Huang, L. (366) 151)

Dependence

Dihydroetorphine; Immunosuppression (Wu, W.-R. (366) 261)

Diadenosine polyphosphate

ATP; Ap₅A (diadenosine pentaphosphate); Ip₅I (diinosine pentaphosphate); Ca²⁺ channels, voltage-dependent (Pintor, J. (366) 159)

Dihydro- β -erythroidine

Nicotinic receptor; Oocyte, *Xenopus laevis*; Methyllycaconitine; Mecamylamine; (Human) (Briggs, C.A. (366) 301)

Dihydroetorphine

Immunosuppression; Dependence (Wu, W.-R. (366) 261)

Dipyridamole

LY-83583; cGMP; Phosphodiesterase; Zaprinast; Phospholipase C; U73122; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

Dizocilpine

Spinal cord; Ischemia; Noradrenaline release; Carrier-mediated release; NMDA receptor; Non-NMDA receptor; LY300168 (GYKI-53655); LY303070 (GYKI-53784) (Nakai, T. (366) 143)

Dopamine

Clozapine; Electrophysiology (Melis, M. (366) R11)

Dotarizine

Flunarizine; Chromaffin cell viability; Ca^{2+} , cytosolic (Novalbos, J. (366) 309)

DP-1904

OKY-046; Thromboxane synthetase inhibitor; Bronchoconstriction; (Guinea pig); (Rat) (Takami, M. (366) 253)

Dynorphin

Substance P; Opioid receptor antagonist; NMDA receptor antagonist; Primary afferent (Arcaya, J.-L. (366) 27)

EDRF (endothelium-derived relaxing factor)

ATP; Thapsigargin; Carbachol; Endothelium; Ca^{2+} level; Cytosolic (Amano, K.-i. (366) 215)

EGLU ((S)- α -ethylglutamate)

mGluR receptor, group II; MCPG ((+)- α -methyl-4-carboxyphenylglycine); DCG = IV ((2S,1R,2R,3R)-2-(2S,1'R,2'R,3'R)-2 (2'3'-dicarboxycyclopropyl)glycine); NAAG (N-acetylasparylglutamate); Hippocampus; Long-term depression (Huang, L. (366) 151)

Electrical field stimulation

Histamine H_3 receptor; (R)- α -methylhistamine; Saphenous human vein; Sympathetic neuron; Cryopreservation (Valentine, A.F. (366) 73)

Electrophysiology

Clozapine; Dopamine (Melis, M. (366) R11)

Emesis

Tachykinin NK_1 receptor; (*Suncus murinus*) (Rudd, J.A. (366) 243)

Endothelial NO synthase

Endothelium-dependent relaxation; Nitric oxide (NO); Fetal bovine serum; Organ culture (Yamawaki, H. (366) 237)

Endothelin ET_A receptor

A-216546; Antagonist (Wu-Wong, J.R. (366) 189)

Endothelium

ATP; Thapsigargin; Carbachol; EDRF (endothelium-derived relaxing factor); Ca^{2+} level; Cytosolic (Amano, K.-i. (366) 215)

K^+ (K_{ATP}) channel, ATP-sensitive; Aorta, rat (Tanaka, Y. (366) R9)

Endothelium-dependent relaxation

Nitric oxide (NO); Endothelial NO synthase; Fetal bovine serum; Organ culture (Yamawaki, H. (366) 237)

Ethanol

Vascular Response; Phenylephrine; Gender; (P-rat) (Stewart, C.W. (366) 55)

Excitatory amino acid

Ischaemia; Reperfusion; Glutamate; Ionotropic; Receptor antagonist (D'Amico, M. (366) 167)

Extensive metabolizer

Cytochrome P-4502D6; [^3H]GBR 12935 binding; Platelet, human; Piperazine acceptor site; Poor metabolizer (Norlén, M. (366) 329)

Fetal bovine serum

Endothelium-dependent relaxation; Nitric oxide (NO); Endothelial NO synthase; Organ culture (Yamawaki, H. (366) 237)

Flunarizine

Dotarizine; Chromaffin cell viability; Ca^{2+} , cytosolic (Novalbos, J. (366) 309)

Gastric mucin biosynthesis

Gastrin; Nitric oxide (NO) synthase; Aging (Ichikawa, T. (366) 87)

Gastrin

Nitric oxide (NO) synthase; Gastric mucin biosynthesis; Aging (Ichikawa, T. (366) 87)

Gender

Ethanol; Vascular Response; Phenylephrine; (P-rat) (Stewart, C.W. (366) 55)

mGluR receptor, group II

MCPG ((+)- α -methyl-4-carboxyphenylglycine); EGLU ((S)- α -ethylglutamate); DCG = IV ((2S,1R,2R,3R)-2-(2S,1'R,2'R,3'R)-2 (2'3'-dicarboxycyclopropyl)glycine); NAAG (N-acetylasparylglutamate); Hippocampus; Long-term depression (Huang, L. (366) 151)

Glutamate

Ischaemia; Reperfusion; Ionotropic; Excitatory amino acid; Receptor antagonist (D'Amico, M. (366) 167)

cGMP

VIP (vasoactive intestinal polypeptide); S-nitrosylated-VIP; Nitric oxide (NO); S-nitrosoglutathione (GSNO); NANC (non-adrenergic non-cholinergic); Smooth muscle; cAMP (Jia, L. (366) 79)

LY-83583; Phosphodiesterase; Zaprinast; Dipyridamole; Phospholipase C; U73122; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

GPIIb/IIIa receptor antagonist

Coronary artery thrombosis; Platelet aggregation; Myocardial infarction; SM-20302 (Huang, J. (366) 203)

G protein

Cystic fibrosis; Lung membrane; Nucleotide; Signal transduction (Laubinger, W. (366) 93)

S-nitrosoglutathione (GSNO)

VIP (vasoactive intestinal polypeptide); S-nitrosylated-VIP; Nitric oxide (NO); NANC (non-adrenergic non-cholinergic); Smooth muscle; cAMP; cGMP (Jia, L. (366) 79)

[^3H]GBR 12935 binding

Cytochrome P-4502D6; Extensive metabolizer; Platelet, human; Piperazine acceptor site; Poor metabolizer (Norlén, M. (366) 329)

Hippocampus

mGluR receptor, group II; MCPG ((+)- α -methyl-4-carboxyphenylglycine); EGLU ((S)- α -ethylglutamate); DCG = IV ((2S,1R,2R,3R)-2-(2S,1'R,2'R,3'R)-2 (2'3'-dicarboxycyclopropyl)glycine); NAAG (N-acetylasparylglutamate); Long-term depression (Huang, L. (366) 151)

Histamine H_3 receptor

(R)- α -methylhistamine; Saphenous human vein; Sympathetic neuron; Electrical field stimulation; Cryopreservation (Valentine, A.F. (366) 73)

Hydrocortisone

Cochlea; Amidotrizoate; ATP; Microcirculation disorder; Reactive oxygen species (Nagura, M. (366) 47)

Immunosuppression

Dihydroetorphine; Dependence (Wu, W.-R. (366) 261)

Intracellular

NMDA receptor; 2,2,2-Trichloroethanol; Ca^{2+} concentration (Scheibler, P. (366) R1)

Ionotropic

Ischaemia; Reperfusion; Glutamate; Excitatory amino acid; Receptor antagonist (D'Amico, M. (366) 167)

Ip₅I (diinosine pentaphosphate)

ATP; Ap₅A (diadenosine pentaphosphate); Diadenosine polyphosphate; Ca^{2+} channels, voltage-dependent (Pintor, J. (366) 159)

Ischaemia

Reperfusion; Glutamate; Ionotropic; Excitatory amino acid; Receptor antagonist (D'Amico, M. (366) 167)

Ischemia

Spinal cord; Noradrenaline release; Carrier-mediated release; NMDA receptor; Non-NMDA receptor; Dizocilpine; LY300168 (GYKI-53655); LY303070 (GYKI-53784) (Nakai, T. (366) 143)

Ischemia and reperfusion injury

P-selectin; Neutrophil; Stunning (Ohnishi, M. (366) 271)

K⁺ (K_{ATP}) channel, ATP-sensitive

Endothelium; Aorta, rat (Tanaka, Y. (366) R9)

Locus coeruleus

Noradrenaline; Voltammetry, in vivo; α_2 -Adrenoceptor subtype (Callado, L.F. (366) 35)

Long-term depression

mGluR receptor, group II; MCPG ((+)- α -methyl-4-carboxyphenylglycine); EGLU ((S)- α -ethylglutamate); DCG = IV ((2S,1R,2R,3R)-2-(2S,1'R,2'R,3'R)-2 (2'3'-dicarboxycyclopropyl)glycine); NAAG (N-acetylaspartylglutamate); Hippocampus (Huang, L. (366) 151)

Lung membrane

Cystic fibrosis; G protein; Nucleotide; Signal transduction (Laubinger, W. (366) 93)

LY-83583

cGMP; Phosphodiesterase; Zaprinast; Dipyridamole; Phospholipase C; U73122; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

LY300168 (GYKI-53655)

Spinal cord; Ischemia; Noradrenaline release; Carrier-mediated release; NMDA receptor; Non-NMDA receptor; Dizocilpine; LY303070 (GYKI-53784) (Nakai, T. (366) 143)

LY303070 (GYKI-53784)

Spinal cord; Ischemia; Noradrenaline release; Carrier-mediated release; NMDA receptor; Non-NMDA receptor; Dizocilpine; LY300168 (GYKI-53655) (Nakai, T. (366) 143)

Masticatory behaviour

Clomipramine; Myosin heavy chain; (Rat) (Hartmann, N. (366) 19)

MCPG ((+)- α -methyl-4-carboxyphenylglycine)

mGluR receptor, group II; EGLU ((S)- α -ethylglutamate); DCG = IV ((2S,1R,2R,3R)-2-(2S,1'R,2'R,3'R)-2 (2'3'-dicarboxycyclopropyl)glycine); NAAG (N-acetylaspartylglutamate); Hippocampus; Long-term depression (Huang, L. (366) 151)

Mecamylamine

Nicotinic receptor; Oocyte, *Xenopus laevis*; Dihydro- β -erythroidine; Methyllcaconitine; (Human) (Briggs, C.A. (366) 301)

Methamphetamine

DADLE ([D-Ala², D-Leu⁵]enkephalin); c-fos mRNA; Opioid (Hayashi, T. (366) R7)

Methyllycaconitine

Nicotinic receptor; Oocyte, *Xenopus laevis*; Dihydro- β -erythroidine; Mecamylamine; (Human) (Briggs, C.A. (366) 301)

Methylxanthine

Acetylcholine; Scopolamine; Turning behavior; Adenosine-dopamine receptor interaction (Casas, M. (366) 1)

Microcirculation disorder

Cochlea; Hydrocortisone; Amidotrizoate; ATP; Reactive oxygen species (Nagura, M. (366) 47)

Monoamine oxidase-B inhibition

Brain oedema; Cholinergic mediation; Motor function; Neuroprotection; Spatial memory (Huang, W. (366) 127)

Motor function

Brain oedema; Cholinergic mediation; Monoamine oxidase-B inhibition; Neuroprotection; Spatial memory (Huang, W. (366) 127)

Muscarinic receptor

Nitric oxide (NO); Nitric oxide (NO) metabolite; Nitric oxide (NO) synthase; Negative chronotropy; Myocyte, cultured (Yamamoto, S. (366) 111)

Myocardial infarction

Coronary artery thrombosis; GPIIb/IIIa receptor antagonist; Platelet aggregation; SM-20302 (Huang, J. (366) 203)

Myocardium

Trabecula; β -adrenoceptor antagonist; Propranolol; Oxygen-free radical; (Rabbit) (Janssen, P.M.L. (366) 223)

Myocyte, cultured

Nitric oxide (NO); Nitric oxide (NO) metabolite; Nitric oxide (NO) synthase; Negative chronotropy; Muscarinic receptor (Yamamoto, S. (366) 111)

Myosin heavy chain

Clomipramine; Masticatory behaviour; (Rat) (Hartmann, N. (366) 19)

NAAG (N-acetylaspartylglutamate)

mGluR receptor, group II; MCPG ((+)- α -methyl-4-carboxyphenylglycine); EGLU ((S)- α -ethylglutamate); DCG = IV ((2S,1R,2R,3R)-2-(2S,1'R,2'R,3'R)-2 (2'3'-dicarboxycyclopropyl)glycine); Hippocampus; Long-term depression (Huang, L. (366) 151)

NANC (non-adrenergic non-cholinergic)

VIP (vasoactive intestinal polypeptide); S-nitrosylated-VIP; Nitric oxide (NO); S-nitrosoglutathione (GSNO); Smooth muscle; cAMP; cGMP (Jia, L. (366) 79)

Negative chronotropy

Nitric oxide (NO); Nitric oxide (NO) metabolite; Nitric oxide (NO) synthase; Muscarinic receptor; Myocyte, cultured (Yamamoto, S. (366) 111)

Neuropathic pain

α_2 -Adrenoceptor antagonist; Atipamezole; Allodynia; Animal model (Xu, M. (366) 41)

Neuroprotection

Brain oedema; Cholinergic mediation; Monoamine oxidase-B inhibition; Motor function; Spatial memory (Huang, W. (366) 127)

Neutrophil

P-selectin; Ischemia and reperfusion injury; Stunning (Ohnishi, M. (366) 271)

Nicotinic receptor

Oocyte, *Xenopus laevis*; Dihydro- β -erythroidine; Methyllycaconitine; Mecamylamine; (Human) (Briggs, C.A. (366) 301)

Nitric oxide (NO)

VIP (vasoactive intestinal polypeptide); S-nitrosylated-VIP; S-nitrosoglutathione (GSNO); NANC (non-adrenergic non-cholinergic); Smooth muscle; cAMP; cGMP (Jia, L. (366) 79)

LY-83583; cGMP; Phosphodiesterase; Zaprinast; Dipyrindamole; Phospholipase C; U73122; Thapsigargin; Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

Nitric oxide (NO) metabolite; Nitric oxide (NO) synthase; Negative chronotropy; Muscarinic receptor; Myocyte, cultured (Yamamoto, S. (366) 111)

L-Arginine; N^G -Nitro-L-arginine; Antiepileptic drug; Pentylentetrazol; Seizure (Czuczwar, S.J. (366) 137)

N^G -Nitro-L-arginine; N^G -Nitro-D-arginine; Chiral inversion; (Ex vivo); (In vivo) (Wang, Y.-X. (366) 175)

BHQ (2,5-di-*t*-butyl-1,4-benzohydroquinone); Superoxide anion; Ca^{2+} channel, Ni^{2+} -sensitive (Fusi, F. (366) 181)

Endothelium-dependent relaxation; Endothelial NO synthase; Fetal bovine serum; Organ culture (Yamawaki, H. (366) 237)

Nitric oxide (NO) metabolite

Nitric oxide (NO); Nitric oxide (NO) synthase; Negative chronotropy; Muscarinic receptor; Myocyte, cultured (Yamamoto, S. (366) 111)

Nitric oxide (NO) synthase

Gastrin; Gastric mucin biosynthesis; Aging (Ichikawa, T. (366) 87)

Nitric oxide (NO); Nitric oxide (NO) metabolite; Negative chronotropy; Muscarinic receptor; Myocyte, cultured (Yamamoto, S. (366) 111)

 N^G -Nitro-D-arginine

N^G -Nitro-L-arginine; Nitric oxide (NO); Chiral inversion; (Ex vivo); (In vivo) (Wang, Y.-X. (366) 175)

 N^G -Nitro-L-arginine

Nitric oxide (NO); L-Arginine; Antiepileptic drug; Pentylentetrazol; Seizure (Czuczwar, S.J. (366) 137)

N^G -Nitro-D-arginine; Nitric oxide (NO); Chiral inversion; (Ex vivo); (In vivo) (Wang, Y.-X. (366) 175)

NMDA receptor

Spinal cord; Ischemia; Noradrenaline release; Carrier-mediated release; Non-NMDA receptor; Dizocilpine; LY300168 (GYKI-53655); LY303070 (GYKI-53784) (Nakai, T. (366) 143)

Promoter inducible; Reporter gene assay; Aequorin (Renard, S. (366) 319)

2,2,2-Trichloroethanol; Ca^{2+} concentration; Intracellular (Scheibler, P. (366) R1)

NMDA receptor antagonist

Substance P; Dynorphin; Opioid receptor antagonist; Primary afferent (Arcaya, J.-L. (366) 27)

Non-NMDA receptor

Spinal cord; Ischemia; Noradrenaline release; Carrier-mediated release; NMDA receptor; Dizocilpine; LY300168 (GYKI-53655); LY303070 (GYKI-53784) (Nakai, T. (366) 143)

Noradrenaline

Locus coeruleus; Voltammetry, in vivo; α_2 -Adrenoceptor subtype (Calado, L.F. (366) 35)

Noradrenaline release

Spinal cord; Ischemia; Carrier-mediated release; NMDA receptor; Non-NMDA receptor; Dizocilpine; LY300168 (GYKI-53655); LY303070 (GYKI-53784) (Nakai, T. (366) 143)

Nucleotide

Cystic fibrosis; G protein; Lung membrane; Signal transduction (Laubinger, W. (366) 93)

OKY-046

DP-1904; Thromboxane synthetase inhibitor; Bronchoconstriction; (Guinea pig); (Rat) (Takami, M. (366) 253)

Oocyte, *Xenopus laevis*

Nicotinic receptor; Dihydro- β -erythroidine; Methyllycaconitine; Mecamylamine; (Human) (Briggs, C.A. (366) 301)

Opioid

DADLE ([D-Ala², D-Leu⁵]enkephalin); *c-fos* mRNA; Methamphetamine (Hayashi, T. (366) R7)

Opioid receptor antagonist

Substance P; Dynorphin; NMDA receptor antagonist; Primary afferent (Arcaya, J.-L. (366) 27)

 μ -Opioid receptor knockout mouse

Visceral pain; Writhing test (Sora, I. (366) R3)

Organ culture

Endothelium-dependent relaxation; Nitric oxide (NO); Endothelial NO synthase; Fetal bovine serum (Yamawaki, H. (366) 237)

Oxygen-free radical

Trabecula; β -adrenoceptor antagonist; Propranolol; Myocardium; (Rabbit) (Janssen, P.M.L. (366) 223)

Oxymetazoline

Prostate; α_1 -Adrenoceptor subtype, α_{1A} , α_{1L} ; (Rat) (Hiraoka, Y. (366) 119)

Parkinson's disease

Bromocriptine; Pergolide; Pramipexole; Ropinirole; Recombinant receptor (Perachon, S. (366) 293)

Passive avoidance

Tetrahydroaminoacridine; D-Cycloserine; Water maze; Alzheimer disease (Riekkinen Jr., P. (366) 13)

Pentylentetrazol

Nitric oxide (NO); L-Arginine; N^G -Nitro-L-arginine; Antiepileptic drug; Seizure (Czuczwar, S.J. (366) 137)

Pergolide

Bromocriptine; Pramipexole; Ropinirole; Parkinson's disease; Recombinant receptor (Perachon, S. (366) 293)

Phenylephrine

Ethanol; Vascular Response; Gender; (P-rat) (Stewart, C.W. (366) 55)

Phorbol ester

Adrenal medulla chromaffin cell; Ca^{2+} concentration, cytosolic free; Protein kinase C; Ca^{2+} channel, voltage-sensitive (Sena, C.M. (366) 281)

Phosphodiesterase

LY-83583; cGMP; Zaprinast; Dipyridamole; Phospholipase C; U73122; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

Phospholipase C

LY-83583; cGMP; Phosphodiesterase; Zaprinast; Dipyridamole; U73122; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

Piperazine acceptor site

Cytochrome *P*-4502D6; Extensive metabolizer; [3 H]GBR 12935 binding; Platelet, human; Poor metabolizer (Norlén, M. (366) 329)

Platelet aggregation

Coronary artery thrombosis; GPIIb/IIIa receptor antagonist; Myocardial infarction; SM-20302 (Huang, J. (366) 203)

Platelet, human

Cytochrome *P*-4502D6; Extensive metabolizer; [3 H]GBR 12935 binding; Piperazine acceptor site; Poor metabolizer (Norlén, M. (366) 329)

Poor metabolizer

Cytochrome *P*-4502D6; Extensive metabolizer; [3 H]GBR 12935 binding; Platelet, human; Piperazine acceptor site (Norlén, M. (366) 329)

Pramipexole

Bromocriptine; Pergolide; Ropinirole; Parkinson's disease; Recombinant receptor (Perachon, S. (366) 293)

Primary afferent

Substance P; Dynorphin; Opioid receptor antagonist; NMDA receptor antagonist (Arcaya, J.-L. (366) 27)

Promoter inducible

NMDA receptor; Reporter gene assay; Aequorin (Renard, S. (366) 319)

Propranolol

Trabecula; β -adrenoceptor antagonist; Myocardium; Oxygen-free radical; (Rabbit) (Janssen, P.M.L. (366) 223)

Prostate

α_1 -Adrenoceptor subtype, α_{1A} , α_{1L} ; Oxymetazoline; (Rat) (Hiraoka, Y. (366) 119)

Protein kinase C

LY-83583; cGMP; Phosphodiesterase; Zaprinast; Dipyridamole; Phospholipase C; U73122; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside (Prasad, R.K. (366) 101)

Adrenal medulla chromaffin cell; Ca^{2+} concentration, cytosolic free; Phorbol ester; Ca^{2+} channel, voltage-sensitive (Sena, C.M. (366) 281)

P-selectin

Ischemia and reperfusion injury; Neutrophil; Stunning (Ohnishi, M. (366) 271)

Reactive oxygen species

Cochlea; Hydrocortisone; Amidotrizoate; ATP; Microcirculation disorder (Nagura, M. (366) 47)

Receptor antagonist

Ischaemia; Reperfusion; Glutamate; Ionotropic; Excitatory amino acid (D'Amico, M. (366) 167)

Recombinant receptor

Bromocriptine; Pergolide; Pramipexole; Ropinirole; Parkinson's disease (Perachon, S. (366) 293)

Reperfusion

Ischaemia; Glutamate; Ionotropic; Excitatory amino acid; Receptor antagonist (D'Amico, M. (366) 167)

Reporter gene assay

NMDA receptor; Promoter inducible; Aequorin (Renard, S. (366) 319)

c-fos mRNA

DADLE ([D-Ala², D-Leu⁵]enkephalin); Methamphetamine; Opioid (Hayashi, T. (366) R7)

mRNA

α_2 -Adrenoceptor; Tail artery rat (McNeill, A.M.C. (366) 233)

Ropinirole

Bromocriptine; Pergolide; Pramipexole; Parkinson's disease; Recombinant receptor (Perachon, S. (366) 293)

Saphenous human vein

Histamine H_3 receptor; (*R*)- α -methylhistamine; Sympathetic neuron; Electrical field stimulation; Cryopreservation (Valentine, A.F. (366) 73)

Sarcoplasmic reticulum

'Superficial buffer barrier' hypothesis; Ca^{2+} -ATPase; Ca^{2+} level, cellular; Ca^{2+} influx; Ca^{2+} channel, L-type; Arterial contraction (Asano, M. (366) 61)

Scopolamine

Acetylcholine; Turning behavior; Methylxanthine; Adenosine-dopamine receptor interaction (Casas, M. (366) 1)

Seizure

Nitric oxide (NO); L-Arginine; N^G -Nitro-L-arginine; Antiepileptic drug; Pentylentetrazol (Czuczwar, S.J. (366) 137)

Signal transduction

Cystic fibrosis; G protein; Lung membrane; Nucleotide (Laubinger, W. (366) 93)

SM-20302

Coronary artery thrombosis; GPIIb/IIIa receptor antagonist; Platelet aggregation; Myocardial infarction (Huang, J. (366) 203)

Smooth muscle

VIP (vasoactive intestinal polypeptide); S-nitrosylated-VIP; Nitric oxide (NO); S-nitrosoglutathione (GSNO); NANC (non-adrenergic non-cholinergic); cAMP; cGMP (Jia, L. (366) 79)

Sodium nitroprusside

LY-83583; cGMP; Phosphodiesterase; Zaprinast; Dipyridamole; Phospholipase C; U73122; Thapsigargin; Nitric oxide (NO); Protein kinase C (Prasad, R.K. (366) 101)

Spatial memory

Brain oedema; Cholinergic mediation; Monoamine oxidase-B inhibition; Motor function; Neuroprotection (Huang, W. (366) 127)

Spinal cord

Ischemia; Noradrenaline release; Carrier-mediated release; NMDA receptor; Non-NMDA receptor; Dizocilpine; LY300168 (GYKI-53655); LY303070 (GYKI-53784) (Nakai, T. (366) 143)

Stunning

P-selectin; Ischemia and reperfusion injury; Neutrophil (Ohnishi, M. (366) 271)

Substance P

Dynorphin; Opioid receptor antagonist; NMDA receptor antagonist; Primary afferent (Arcaya, J.-L. (366) 27)

‘Superficial buffer barrier’ hypothesis

Sarcoplasmic reticulum; Ca^{2+} -ATPase; Ca^{2+} level, cellular; Ca^{2+} influx; Ca^{2+} channel, L-type; Arterial contraction (Asano, M. (366) 61)

Superoxide anion

BHQ (2,5-di-*t*-butyl-1,4-benzohydroquinone); Nitric oxide (NO); Ca^{2+} channel, Ni^{2+} -sensitive (Fusi, F. (366) 181)

Sympathetic neuron

Histamine H_3 receptor; (*R*)- α -methylhistamine; Saphenous human vein; Electrical field stimulation; Cryopreservation (Valentine, A.F. (366) 73)

Tachykinin NK₁ receptor

Emesis; (*Suncus murinus*) (Rudd, J.A. (366) 243)

Tail artery rat

α_2 -Adrenoceptor; mRNA (McNeill, A.M.C. (366) 233)

Tetrahydroaminoacridine

D-Cycloserine; Water maze; Passive avoidance; Alzheimer disease (Riekinen Jr., P. (366) 13)

Thapsigargin

LY-83583; cGMP; Phosphodiesterase; Zaprinast; Dipyridamole; Phospholipase C; U73122; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

ATP; Carbachol; Endothelium; EDRF (endothelium-derived relaxing factor); Ca^{2+} level; Cytosolic (Amano, K.-i. (366) 215)

Thromboxane synthetase inhibitor

DP-1904; OKY-046; Bronchoconstriction; (Guinea pig); (Rat) (Takami, M. (366) 253)

Trabecula

β -adrenoceptor antagonist; Propranolol; Myocardium; Oxygen-free radical; (Rabbit) (Janssen, P.M.L. (366) 223)

2,2,2-Trichloroethanol

NMDA receptor; Ca^{2+} concentration; Intracellular (Scheibler, P. (366) R1)

Turning behavior

Acetylcholine; Scopolamine; Methylxanthine; Adenosine-dopamine receptor interaction (Casas, M. (366) 1)

U73122

LY-83583; cGMP; Phosphodiesterase; Zaprinast; Dipyridamole; Phospholipase C; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)

Vascular Response

Ethanol; Phenylephrine; Gender; (P-rat) (Stewart, C.W. (366) 55)

S-nitrosylated-VIP

VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); S-nitrosogluthathione (GSNO); NANC (non-adrenergic non-cholinergic); Smooth muscle; cAMP; cGMP (Jia, L. (366) 79)

VIP (vasoactive intestinal polypeptide)

S-nitrosylated-VIP; Nitric oxide (NO); S-nitrosogluthathione (GSNO); NANC (non-adrenergic non-cholinergic); Smooth muscle; cAMP; cGMP (Jia, L. (366) 79)

Visceral pain

Writhing test; μ -Opioid receptor knockout mouse (Sora, I. (366) R3)

Voltammetry, in vivo

Locus coeruleus; Noradrenaline; α_2 -Adrenoceptor subtype (Callado, L.F. (366) 35)

Water maze

Tetrahydroaminoacridine; D-Cycloserine; Passive avoidance; Alzheimer disease (Riekinen Jr., P. (366) 13)

Writhing test

Visceral pain; μ -Opioid receptor knockout mouse (Sora, I. (366) R3)

Zaprinast

LY-83583; cGMP; Phosphodiesterase; Dipyridamole; Phospholipase C; U73122; Thapsigargin; Nitric oxide (NO); Sodium nitroprusside; Protein kinase C (Prasad, R.K. (366) 101)